<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00159536</url>
  </required_header>
  <id_info>
    <org_study_id>PregMet</org_study_id>
    <nct_id>NCT00159536</nct_id>
  </id_info>
  <brief_title>Metformin in Pregnant PCOS Women</brief_title>
  <acronym>PregMet</acronym>
  <official_title>Metformin Treatment of Pregnant Women With Polycystic Ovary Syndrome (PCOS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Norwegian University of Science and Technology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the effect of metformin on pregnancy complications and pregnancy outcome in
      the II. and III. trimester of pregnancy in women with polycystic ovary syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gestational diabetes</measure>
    <time_frame>up to delivery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence of metabolic syndrome and neurophysiologic parameters in offspring</measure>
    <time_frame>Within 18 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Preterm delivery</measure>
    <time_frame>up to delivery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>pre-eclampsia</measure>
    <time_frame>up to delivery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>emesis and hyperemesis</measure>
    <time_frame>up to delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breastfeeding</measure>
    <time_frame>One year post partum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>weight change</measure>
    <time_frame>up to delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure change</measure>
    <time_frame>up to delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incident of instrumental deliveries</measure>
    <time_frame>at delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormone levels in mother and offspring</measure>
    <time_frame>up to delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Snoring and sleep quality</measure>
    <time_frame>up to delivery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">257</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin 1000mg x 2 daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo x 2 daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 1000 mg x 2 per day. Orally. From inclusion (before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>metformin from Weifa 500 mg / tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, 2 tablets x 2 daily.Orally. From inclusion (that is before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Placebo from Weifa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-45 years,

          -  PCOS diagnosis according to Rotterdam criteria

          -  single, viable, ultrasound verified fetus

          -  if metformin was used at conception and early pregnancy, at least 7 days of &quot;wash out&quot;

        Exclusion Criteria:

          -  known liver disease or ALAT &gt; 90 nmol/L

          -  known renal disease or creatinine &gt; 110 micromol/L

          -  diabetes mellitus

          -  alcohol or drug abuse

          -  peroral steroid treatment

          -  cimetidine, anticoagulant or erythromycin treatment at time of inclusion

          -  not suitable for other reasons
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eszter I Vanky, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Norwegian University of Science and Technology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University hospital of Bergen</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Hospital of Northern Norway</name>
      <address>
        <city>Bodø</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Buskerud Hospital</name>
      <address>
        <city>Drammen</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haugesund Hospital</name>
      <address>
        <city>Haugesund</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ringerike Hospital</name>
      <address>
        <city>Hønefoss</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elvebredden Gynekologpraksis</name>
      <address>
        <city>Kristiansand</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lillehammer Hospital</name>
      <address>
        <city>Lillehammer</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Departments of Obstetrics and Gynecology and Endocrinology, St. Olav's Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ålesund Hospital</name>
      <address>
        <city>Ålesund</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Underdal MO, Stridsklev S, Oppen IH, Høgetveit K, Andersen MS, Vanky E. Does metformin treatment during pregnancy modify future metabolic profile in women with PCOS? J Clin Endocrinol Metab. 2018 Apr 5. doi: 10.1210/jc.2018-00485. [Epub ahead of print]</citation>
    <PMID>29659896</PMID>
  </reference>
  <results_reference>
    <citation>Vanky E, Stridsklev S, Heimstad R, Romundstad P, Skogøy K, Kleggetveit O, Hjelle S, von Brandis P, Eikeland T, Flo K, Berg KF, Bunford G, Lund A, Bjerke C, Almås I, Berg AH, Danielson A, Lahmami G, Carlsen SM. Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study. J Clin Endocrinol Metab. 2010 Dec;95(12):E448-55. doi: 10.1210/jc.2010-0853. Epub 2010 Oct 6.</citation>
    <PMID>20926533</PMID>
  </results_reference>
  <results_reference>
    <citation>Vanky E, Carlsen SM. Androgens and antimüllerian hormone in mothers with polycystic ovary syndrome and their newborns. Fertil Steril. 2012 Feb;97(2):509-15. doi: 10.1016/j.fertnstert.2011.11.021. Epub 2011 Dec 10.</citation>
    <PMID>22154766</PMID>
  </results_reference>
  <results_reference>
    <citation>Shetelig Løvvik T, Stridsklev S, Carlsen SM, Salvesen Ø, Vanky E. Cervical Length and Androgens in Pregnant Women With Polycystic Ovary Syndrome: Has Metformin Any Effect? J Clin Endocrinol Metab. 2016 Jun;101(6):2325-31. doi: 10.1210/jc.2015-3498. Epub 2016 Feb 2.</citation>
    <PMID>26835542</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PCOS</keyword>
  <keyword>metformin</keyword>
  <keyword>pregnancy</keyword>
  <keyword>preeclampsia</keyword>
  <keyword>diabetes</keyword>
  <keyword>preterm delivery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

